Publications by authors named "Annabell Roberti"

The mononuclear phagocyte system includes monocytes, macrophages, some dendritic cells, and multinuclear giant cells. These cell populations display marked heterogeneity depending on their differentiation from embryonic and bone marrow hematopoietic progenitors, tissue location, and activation. They contribute to tissue homeostasis by interacting with local and systemic immune and non-immune cells through trophic, clearance, and cytocidal functions.

View Article and Find Full Text PDF
Article Synopsis
  • Loss-of-function mutations in the HTRA1 protein lead to cerebral vasculopathy, a condition that affects brain blood vessels.
  • The study identifies an HTRA1 variant that effectively corrects trimer assembly defects, restoring its enzymatic function, as well as a peptidic ligand that activates HTRA1 monomers.
  • Findings suggest potential strategies for targeted protein repair, offering hope for therapeutic approaches to conditions related to HTRA1 mutations.
View Article and Find Full Text PDF

Inflammation is a driver of human disease and an unmet clinical need exists for new anti-inflammatory medicines. As a key cell type in both acute and chronic inflammatory pathologies, macrophages are an appealing therapeutic target for anti-inflammatory medicines. Drug repurposing - the use of existing medicines for novel indications - is an attractive strategy for the identification of new anti-inflammatory medicines with reduced development costs and lower failure rates than de novo drug discovery.

View Article and Find Full Text PDF

Drug repurposing is an attractive, pragmatic approach to drug discovery that has yielded success across medical fields over the years. The use of existing medicines for novel indications enables dramatically reduced development costs and timescales compared with drug discovery and is therefore a promising strategy in cardiovascular disease, where new drug approvals lag significantly behind that of other fields. Extensive evidence from pre-clinical and clinical studies show that chronic inflammation is a driver of pathology in cardiovascular disease, and many efforts have been made to target cardiovascular inflammation therapeutically.

View Article and Find Full Text PDF

NF-κB is a central mediator of inflammation, response to DNA damage and oxidative stress. As a result of its central role in so many important cellular processes, NF-κB dysregulation has been implicated in the pathology of important human diseases. NF-κB activation causes inappropriate inflammatory responses in diseases including rheumatoid arthritis (RA) and multiple sclerosis (MS).

View Article and Find Full Text PDF